diabetestalk.net

Eli Lilly Diabetes

Eli Lilly Expands Diabetes R&d Efforts With New Partnership

Eli Lilly Expands Diabetes R&d Efforts With New Partnership

Eli Lilly’s diabetes portfolio is getting bigger. The pharmaceutical company announced on Thursday a new collaboration with Swiss biotech KeyBioscience AG that could yield a novel series of diabetes therapies called Dual Amylin Calcitonin Receptor Agonists (DACRAS). DACRAS are designed to work by simultaneously activating the calcitonin and amylin receptors, which could initiate effects like improved insulin sensitivity, better blood glucose control, suppressed food intake, and weight reduction. The DACRAS platform includes multiple molecules, but the prominent ones include KBP-042, KBP-089 and KBP-056. KBP-042 has already started phase II development while the others are either in the pre-clinical or phase I stage. Eli Lilly will give KeyBioscience an initial payment of $55 million with the potential to gain more based on certain development, regulatory, and commercialization milestones. Lilly will gain worldwide development and commercialization rights to these molecules. "We are extremely excited about the promise of this new mechanism, which could potentially improve insulin sensitivity, reduce weight and improve blood glucose control," said Morten Karsdal, chairman of the board, KeyBioscience AG, in a statement. "The dual activation of the calcitonin and amylin receptors is exciting research in the diabetes space. We look forward to partnering with Lilly to advance this important work." In May, Lilly unveiled a new effort to invest $850 million in its U.S. operations in 2017 with a focus being on expanding its manufacturing capabilities in the diabetes space. This announcement comes on the eve of the 77th annual meeting of the American Diabetes Association taking place in San Diego, California. Continue reading >>

Disney And Lilly Diabetes

Disney And Lilly Diabetes

Lilly is an expert in type 1 diabetes, and no one knows families like Disney. Now, these two companies have come together to create special resources for families like yours. From Disney Publishing comes a series of books for children of different ages and at varying stages of type 1 diabetes. The different themes include sports stories from ESPN, familiar characters like Hannah Montana™, adventures with Mickey Mouse and his friend Coco, a fun-loving monkey who has type 1 diabetes, and more. Here on T1EverydayMagic.com, there are lots of helpful features for your family, including blogs where you can get tips, feedback, and support from other parents. Together, Lilly’s expertise in type 1 diabetes and Disney’s magic can help keep your child and your family feeling inspired and empowered to live a full, active life with type 1 diabetes! Disney’s books with Lilly are distributed through doctors’ offices. Ask your healthcare team about getting your hands on one today! Visit T1EverydayMagic.com to read digital versions of select Disney and Lilly books, watch videos, and find info on more helpful resources by Disney and Lilly Diabetes. All trademarks are the property of their respective owners. Continue reading >>

Why Eli Lilly Is Gouging Diabetes Drug Share From Dow's J&j, Others

Why Eli Lilly Is Gouging Diabetes Drug Share From Dow's J&j, Others

Eli Lilly (LLY) is gouging share from Johnson & Johnson (JNJ) and Novo Nordisk (NVO) in two classes of diabetes drugs, an analyst said Monday, though he suggested Lilly's second-quarter metrics would just meet consensus views. Prescription trends show Lilly's sales and earnings will be roughly in line with Wall Street views, Leerink analyst Seamus Fernandez wrote in a note to clients. The consensus expects Lilly to report $1.04 in adjusted earnings per share on $5.59 billion in sales. But Fernandez upped his price target on Lilly stock to 93 from 90, noting that diabetes drugs Taltz and Trulicity are doing well. Meanwhile, Lilly's Jardiance and Trulicity are displacing drugs from Dow's J&J and Novo Nordisk in the SGLT-2 and GLP-1 classes of diabetes drugs, respectively. U.S. prescriptions of SGLT-2 diabetes drugs grew 17% year over year and 6% sequentially in the second quarter, Fernandez said. At the same time, prescriptions from the GLP-1 class of diabetes drugs grew 24% vs. the year-earlier period and 108% quarter over quarter. IBD'S TAKE: In the biotech space, Exelixis stock has popped 69% this year on its kidney cancer treatment. Head to The New America for a closer look at what catalysts are upcoming for this stock. In the SGLT-2 space, Lilly's Jardiance is taking share from J&J's Invokana. A study by J&J showed Invokana can reduce cardiovascular events in diabetes patients, but it also comes with a greater risk of amputation. The study "validated the class' (cardiovascular) benefit," Fernandez said. But it also "provided a clear tailwind to Lilly's Jardiance which saw accelerated growth in Q2 of 74% year over year and 19% sequential growth compared with 68% year-over-year and 14% sequential growth in Q1." He expects Jardiance to overtake Invokana in the SGLT-2 cl Continue reading >>

Contact The Lilly Answers Center At 1-800-lillyrx (1-800-545-5979)

Contact The Lilly Answers Center At 1-800-lillyrx (1-800-545-5979)

Thank you for your interest in contacting Lilly. By calling this telephone number, you will have access to a healthcare provider who can provide additional information similar to what you can find on this website. The toll-free number is a service provided by Eli Lilly and Company and is not intended to replace the advice of your healthcare team. If you have a medical emergency, you should immediately call 911 (or your local emergency services number). If you are seeking medical advice, you should direct those questions to your healthcare team. Your own healthcare team is the best source of information regarding your health. Continue reading >>

News: Lilly Developing Its Own Insulin Pump And Smart Pen Device

News: Lilly Developing Its Own Insulin Pump And Smart Pen Device

In the next two or three years, Eli Lilly wants to become more than just an insulin company. The Indianapolis-based Pharma giant has been quietly working on diabetes technology behind the scenes since 2015, and just recently publicly disclosed that it's working specifically on a tubed insulin pump with infusion set and a smart insulin pen that will deliver insulin, track data, and communicate with the Dexcom CGM for a full mobile health offering. Yup, in mid-November Lilly announced it had signed a development agreement with Dexcom to weave that CGM data into its future connected devices. Two articles from the Wall Street Journal and FierceBiotech expanded on that news by delving into the broader "connected diabetes ecosystem" the company says it's developing. This all comes at a time of a major shift in the D-Tech market, with insulin pump choice evaporating thanks to JnJ Animas being shut down and Roche stopping its sales of insulin pumps, along with uncertainty about Tandem's future. Medtronic remains as the big behemoth in diabetes devices, while OmniPod remains the only patch pump in the USA. Most of these vendors are now looking more at closed loop systems rather than stand-alone insulin pumps. On the CGM side, Dexcom and Medtronic may be facing a new kind of competition from the new Abbott Freestyle Libre, a simpler sort of CGM that requires no fingerstick calibrations. With Lilly publicly putting its name in the ring as a device maker, we may soon be seeing an interesting new dynamic in the market... Lilly's Diabetes Tech Pipeline Here's a snapshot of what we understand is in the works, garnered from a combination of what we've been told directly by Lilly Diabetes and what the WSJ reported: Connected Diabetes Ecosystem: This is the term Lilly's throwing around f Continue reading >>

Lilly Diabetes 250

Lilly Diabetes 250

For the state road called "Indiana 250", see Indiana State Road 250. The Lilly Diabetes 250[1] is a NASCAR Xfinity Series auto race held at the Indianapolis Motor Speedway since 2012. It takes place the Saturday of Kroger Super Weekend.[2][3] This race replaced the Kroger 200, which had been held at the nearby Lucas Oil Raceway at Indianapolis, formerly known as Indianapolis Raceway Park, for the previous 30 years. Brad Keselowski won the inaugural event. For 2016, as part of the Xfinity "Dash for Cash" format, the race was 250 miles in total, but two 20-lap heat races, similar to the Can-Am Duel, was to be added to be run prior to the 60-lap main event. In 2017 it will not continue the heat races and instead use the new stage format with stages 1 and 2 being 25 laps each, and stage 3 being 50 laps. In addition, the event will not be a Dash for Cash event and that has been moved to Phoenix's Spring event. In late-June 2017, due to drivers saying that they could go easily 25 laps on tires and fuel, NASCAR increased the length of stages 1 and 2 from 25 laps to 30 laps each, with the final 40 laps making up Stage 3. Past winners[edit] Year Date No. Driver Team Manufacturer Race Distance Race Time Average Speed (mph) Laps Miles (km) 2012 July 28 22 Brad Keselowski Penske Racing Dodge 100 250 (402.336) 1:59:00 126.05 2013 July 27 54 Kyle Busch Joe Gibbs Racing Toyota 100 250 (402.336) 1:51:26 134.61 2014 July 26 3 Ty Dillon Richard Childress Racing Chevrolet 100 250 (402.336) 1:49:22 137.153 2015 July 25 54 Kyle Busch Joe Gibbs Racing Toyota 100 250 (402.336) 1:49:52 136.529 2016* July 23 18 Kyle Busch Joe Gibbs Racing Toyota 63* 157.5 (253.471) 1:09:20 136.298 2017 July 22 9 William Byron JR Motorsports Chevrolet 100 250 (402.336) 1:58:50 126.227 2016: The main event was re Continue reading >>

Eli Lilly Fronts $55m For Rights To Keybioscience’s Diabetes Drugs

Eli Lilly Fronts $55m For Rights To Keybioscience’s Diabetes Drugs

Xconomy Indiana — With competition threatening to chip away at its diabetes stronghold, Eli Lilly is shoring up its pipeline with a deal that gives the company access to a potential new class of diabetes drugs. Indianapolis-based Lilly (NYSE: LLY) has agreed to pay $55 million up front to KeyBioscience in exchange for rights to compounds in various stages of development as treatments for type 2 diabetes and other metabolic disorders. KeyBioscience, a subsidiary of Denmark-based Nordic Bioscience, will be eligible for additional payments tied to development and regulatory milestones. If drugs from the collaboration reach the market, KeyBioscience would receive royalties from drug sales. Lilly was drawn to KeyBioscience’s drug technology, which could offer an advantage over its current lineup of diabetes drugs. The Dual Amylin Calcitonin Receptor Agonists (DACRA) drug platform develops drugs to hit two targets, the calcitonin and amylin receptors. The companies say that acting on both receptors could have a range of benefits including improving insulin sensitivity, suppressing food intake, and causing weight reduction. KeyBioscience’s lead drug, KBP-042, has started Phase 2 clinical trials. The deal gives Lilly global rights to that compound and others from the DACRA platform. Lilly’s top seller last year was Humalog, a fast-acting injectable insulin that accounted for $2.7 billion of the company’s $21.2 billion in revenue. Humalog’s 2016 sales were down 3 percent compared to 2015. Though Humalog has lost patent protection, it hasn’t experienced steep drops in sales yet. That’s because as a biological drug, it’s harder for competitors to develop biologically similar products. Analysts expect Humalog will begin facing competition from so-called biosimilar Continue reading >>

New Diabetes Meds Push Lilly To Earnings Beat But Pipeline Worries Abound

New Diabetes Meds Push Lilly To Earnings Beat But Pipeline Worries Abound

It was less than two weeks ago that Eli Lilly stunned investors with unexpected bad news about its highly anticipated rheumatoid arthritis drug baricitinib, which was spurned by the FDA even after the company was given three extra months to address safety concerns. And that news, of course, followed the high-profile failure of Lilly’s phase 3 Alzheimer’s drug solanezumab. So, investors were in the mood for some good news—and they got a bit of it in Lilly’s first-quarter earnings report, even as concerns about the company’s pipeline cast a cloud over the numbers. Lilly’s first-quarter sales grew 7% year-over-year to $5.2 billion, thanks to strong uptake of some of its newer drugs, including Trulicity, its once-weekly GLP-1 diabetes med, and its psoriasis drug Taltz. Its non-GAAP net income was up 18% to $1 billion, or 98 cents per share. Analysts had been expecting EPS of 96 cents on average. RELATED: Biopharma's Q1 earnings, all in one place But some weak spots in the quarter gave analysts pause. Lilly's diabetes news wasn't all sunny; sales of its insulin therapy Humulin fell 12% year-over-year to $314.5 million, way below the consensus estimate of $345 million. Lilly’s new SGLT2 diabetes medicine Jardiance nearly doubled in sales to $74 million during the quarter, but Credit Suisse analysts were hoping for more, telling investors in a note that “uptake remains below our expectations.” Jardiance was expected to get a boost after Lilly won FDA approval to market the med to reduce the risk of cardiovascular death. Enrique Conterno, president of Lilly Diabetes, said during an investor conference call that the company saw a 70% increase in new patient starts during the quarter, far above the 30% growth SGLT2 drugs achieved overall. But Conterno acknowledg Continue reading >>

Diabetes Advocates Protest At Eli Lilly About Insulin Prices

Diabetes Advocates Protest At Eli Lilly About Insulin Prices

On Saturday, September 9th, 2017 a group of diabetes patient advocates organized by T1International and People of Faith for Access to Medicines (PFAM) showed up in front of Eli Lilly’s Headquarters in Indianapolis, Indiana to protest rising insulin prices. Eli Lilly is one of the three top insulin manufacturers. The company markets Basaglar, Glucagon, Humalog, and other diabetes products. They are currently being sued in class action suit along with the other insulin makers, Sanofi and Novo Nordisk. T1International, an advocacy group who launched the initiative #insulin4all wrote on their blog that this protest was about those living with diabetes speaking up against the prices that ensure their survival. They want transparency about the costs associated with making insulin and the profits they make. They also want them to “commit to stopping the immoral act of price gouging people who depend on this medicine for survival.” Their specific requests to Eli Lilly: Be transparent about how much it costs to make one vial of Humalog insulin Be transparent about your profits from each vial Lower the price of insulin Involved in the protests were also parents of children with type 1 diabetes. One was Meri Schuhmacher-Jackson who blogs about life with 3 children with type 1 diabetes and commented on her reason for showing up to the protest: I went to the protest because I’m tired of doing nothing. It’s so easy to say, “This won’t change anything”…but certainly we must try. It turns out, there were newspapers there, there were radio stations there, and the story ended up on the front page of the Sunday paper. More people are made aware now than last week. I understand the entire world didn’t hear our cries…but if we’re lucky, the right person heard. We can Continue reading >>

Eli Lilly Builds $23b-plus Sales Forecast On Diabetes, Cancer Launches

Eli Lilly Builds $23b-plus Sales Forecast On Diabetes, Cancer Launches

Eli Lilly is betting that its new drugs will kick off an era of growth, but the company will have to contend with a tough environment in diabetes and a hefty patent expiration as it aims for 2018 revenue of $23 billion to $23.5 billion. In its annual presentation of its outlook for the year ahead, Lilly said on Wednesday that its 2018 growth will be driven by its newest diabetes drugs—Trulicity, Basaglar and Jardiance—plus plaque psoriasis treatment Taltz and cancer offerings Verzenio, Cyramza, and Lartruvo. Rheumatoid arthritis medication Olumiant, approved in Europe but so far spurned by the FDA, is still factored into Lilly's ambitions for the coming years, Lilly CEO David Ricks said in a statement. Ricks contends that the company is in the "early stages of a growth period" driven by those new launches. RELATED: Sanofi wins approval of Admelog with plans to snatch some of Humalog's blockbuster sales But it won't be smooth sailing ahead. Cialis, the erectile dysfunction drug that's long been a top performer for Lilly, is nearing the end of its patent life, and when generics hit, sales are expected to plummet, creating a big gap to fill. Lilly will also face its first full year of generic competition to ADHD drug Strattera, blood thinner Effient and testosterone med Axiron, Bernstein analyst Tim Anderson pointed out. Plus, Lilly is likely to experience more pressure on its diabetes business next year as its key new launches are getting into gear. Sanofi has just won an FDA nod for Admelog, a follow-on biologic that will go up against Lilly's top seller Humalog, and it's facing new competition for its fast-growing Trulicity. Novo Nordisk's brand-new Ozempic, a weekly diabetes injection formerly known as semaglutide, recently won FDA approval and boasts favorable hea Continue reading >>

Lilly Diabetes Drug Jardiance Falls Short

Lilly Diabetes Drug Jardiance Falls Short

Jardiance misses predictions, but top-selling Humalog beats Full-year sales forecast range trails; shares decline Eli Lilly & Co.’s promising diabetes drug Jardiance fell short last quarter, a sign of the major challenges ahead for its new chief executive officer after recent setbacks on other potential new treatments. Jardiance’s first-quarter sales, at $74 million, were well below the $93.6 million average of analysts’ estimates. The shares dropped 2.6 percent to $81.29 at 9:39 a.m. in New York. For new CEO David Ricks, who succeeded John Lechleiter at the start of the year, 2017 is shaping up as more challenging than might have been expected a few months ago. Jardiance’s shortfall may be further evidence of the price pressure manufacturers of diabetes treatments are facing. And after the recent experimental setbacks, Lilly is more reliant on existing treatments to fuel future growth. Mute Current Time 0:00 / Duration Time 0:00 Loaded: 0% Progress: 0% Stream TypeLIVE Remaining Time -0:00 Playback Rate 1 Chapters Chapters captions settings, opens captions settings dialog captions off, selected Captions This is a modal window. An error has occurred. Reload the web page or use another browser. Error 5 Caption Settings Dialog Beginning of dialog window. Escape will cancel and close the window. TextColorWhiteTransparencyOpaqueBackgroundColorBlackTransparencyOpaqueWindowColorBlackTransparencyTransparent Font Size50% Text Edge StyleNone Font FamilyProportional Sans-Serif Eli Lilly CEO Says Diabetes Is ‘Core Engine’ to Strategy Eli Lilly CEO Says Diabetes Is ‘Core Engine’ to Strategy x Share Embed Permalink Two other new treatments, cancer drug Cyramza and diabetes treatment Basaglar, also came in lower than predicted last quarter. But there were some bright s Continue reading >>

Eli Lilly Bets Big On Insulin-delivery Devices

Eli Lilly Bets Big On Insulin-delivery Devices

CAMBRIDGE, Mass.—Eli Lilly & Co., one of the biggest makers of insulin, has been planning a risky new business venture: making the high-tech devices that deliver insulin to diabetes patients. In a research laboratory Lilly opened here in 2015, scientists have been developing a wearable, automated insulin-delivery device designed to reduce the decision-making and guesswork of conventional insulin injections. They are also developing a “smart pen” injection device that can wirelessly transmit dosing information to a patient’s phone, to ensure proper dosing. Lilly’s previously undisclosed projects, for which the company has enlisted several design and device-firm partners, including the inventor of the Segway scooter, is an unusual example of diversification at a time when much of the drug industry is moving in the opposite direction—shedding nondrug businesses to focus on pharmaceuticals. Indianapolis-based Lilly, the first company to mass produce insulin in 1923, faces competitive pressures including the expected arrival of lower-cost copies of its top-selling insulin, Humalog. And it sees growth in the market for advanced insulin-delivery devices. Enrique Conterno, head of Lilly’s diabetes business, said he believed Lilly’s insulin business would become “obsolete” if the company remained largely an insulin provider without delivery systems. “Do we want to be just an insulin provider that just goes into a system, or do we want to be the integrator of the system?” he said at the Cambridge lab this month. “To me, it’s clear where the business is going.” ​Lilly’s insulin products currently generate about 20% of the company’s total revenue. Still, the projects are a risky bet because Lilly will compete with medical-device heavyweights like Continue reading >>

Lilly Makes Big Push Into Devices To Protect Diabetes Sales

Lilly Makes Big Push Into Devices To Protect Diabetes Sales

Lilly makes big push into devices to protect diabetes sales Eli Lilly has unveiled its device-driven strategy for weathering the competitive and pricing pressures faced by its diabetes unit. The Big Pharma is working on insulin delivery devices that move it onto Medtronics turf and has teamed up with Dexcom to add continuous glucose monitoring systems to its arsenal. Lilly has quietly worked on an automated, wearable insulin delivery device and smart pen injector at a lab it opened in 2015, The Wall Street Journal reports . The facility in Cambridge, Mass., employs about 40 people with backgrounds far outside of Lilly's traditional core competencies, such as mechanical engineering, material science and industrial design. Lilly has bolstered the capabilities of its team by enlisting the support of an R&D group run by the inventor of the Segway scooter. The Big Pharma set up the unit after intuiting that the future of the diabetes market will belong to companies that monitor patients and deliver drugs rather than the businesses that make insulin itself. Like this story? Subscribe to FierceBiotech! Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go. RELATED: Medtronics long-awaited artificial pancreas makes U.S. debut That, like all R&D, is something of a risk, especially because it moves Lilly onto unfamiliar territory colonized by big businesses. Medtronic won FDA approval for an automated insulin delivery device last year and a clutch of other small and large medical technology companies are giving chase. Lillys entrant to t Continue reading >>

Lilly Diabetes Journey Awards℠

Lilly Diabetes Journey Awards℠

The Lilly Diabetes Journey Awards program recognizes people with type 1 diabetes who have successfully managed diabetes with insulin for 10, 25, 50, or 75 years. At Lilly Diabetes, we recognize that every person with type 1 diabetes is on a unique and challenging lifelong journey. But they’re not alone—and while we work hard to equip people with the resources they need to help overcome challenges, we’re also here to celebrate the successes. The Lilly Diabetes Journey Awards program has recognized thousands of individuals who have successfully managed their diabetes for 10, 25, 50, even 75 years. The awards are meant to honor those who have long been successful, but also to inspire others to believe they can do it, too. Healthcare professionals can also support and honor patients in their community with a live presentation Journey Awards ceremony. Those who receive Lilly Diabetes Journey Awards are a testament to all people with diabetes that learning how to manage their health and adapting to the ever-changing technology of diabetes care can lead to a long and successful diabetes journey. Medals Medals are presented to people with diabetes in the United States throughout the year. Applicants must have type 1 diabetes and must have been taking any brand of insulin continuously for 10, 25, 50, or 75 years to qualify. Each recipient receives an elegant award, beautifully engraved with their name, along with a signed letter from our CEO, Dave Ricks, encouraging their continued success. We also invite 75-year award recipients to have their names engraved on a special monument on our Indianapolis campus. This monument is a tribute to lives well-lived with type 1 diabetes and reminds us of the long history we share with those who are able to live long, healthy lives by m Continue reading >>

Dexcom, Eli Lilly Ink Diabetes Ecosystem Deal

Dexcom, Eli Lilly Ink Diabetes Ecosystem Deal

Two leaders to combine tools aimed at reducing complexity and burden while improving outcomes in diabetes management SAN DIEGO--(BUSINESS WIRE)-- DexCom (NASDAQ: DXCM), the leader in continuous glucose monitoring (CGM) for people with diabetes, today announced a development agreement with Eli Lilly and Company (NYSE: LLY) to include Dexcom CGM into Lilly’s Connected Diabetes Ecosystem. The companies expect to combine Lilly’s smart insulin delivery devices and Dexcom CGM to improve the future of diabetes management. “Lilly’s Connected Diabetes Ecosystem promises to drive a significant step forward in diabetes management. As technology converges in our industry, we believe that connected systems will become the standard of care over time,” said Kevin Sayer, President and CEO of Dexcom. “By combining devices, drugs and technology, we can deliver solutions that adapt to each person’s unique needs in managing their diabetes while also providing compelling advancements for both physicians and payers.” Through the Connected Diabetes Ecosystem, the companies aim to provide a comprehensive solution to people with diabetes. Devices such as CGM, smart-pens and insulin pumps, drugs, apps and other analytical tools will be aimed at improving outcomes. Clinical trials are expected to begin by the end of 2017. “The Connected Diabetes Ecosystem relies not only on Lilly’s core diabetes expertise, but also the strength of our key partners such as Dexcom,” said Enrique Conterno, president, Lilly Diabetes and Lilly USA. “Dexcom will be an important collaborator in our mission to improve outcomes and reduce the daily burden for people with diabetes.” About DexCom, Inc. (NASDAQ: DXCM) DexCom, Inc., headquartered in San Diego, CA, is dedicated to helping people bette Continue reading >>

More in diabetes